Sonali M. Smith, MD
Associate Professor of Medicine
Director, Lymphoma Program
Dr. Sonali M. Smith is an expert in the care and treatment of adults with all types of Hodgkin and non-Hodgkin lymphoma. She has a special interest in new agents for lymphoma, as well as stem cell transplantation and its role in improving the survival of patients with relapsed lymphomas.
An active researcher, Dr. Smith is involved in the development of promising agents for patients with non-Hodgkin and Hodgkin lymphoma. She is principal investigator on a number of innovative clinical trials. Many of the trials incorporate the collection of tumor and blood samples to study the effects of treatment on cancer cells through collaborative laboratories.
Dr. Smith frequently lectures to both physicians and patient groups on these topics. She serves on several national committees charged with improving treatment options for patients with lymphoma, providing physician education, and providing reliable information for patients through established websites. Dr. Smith also frequently performs peer reviews of research being considered for publication in major medical journals. Additionally, she has won several teaching awards at the University of Chicago.
Duchossois Center for Advanced Medicine
Year Started Practice
Northwestern University Medical School
Northwestern University, Chicago
The University of Chicago Medicine
American Association for Cancer Research
Office Postal Address
Sonali M. Smith, MD
Physicians, contact the
Learn More About Dr. Smith
After suffering from episodes of chest pain and feeling faint, Warren Bratton came to the University of Chicago Medicine -- where he was diagnosed with a rare form of lymphoma. He credits an aggressive chemotherapy approach, and expert care from Dr. Smith, with saving his life. Read the story.
Dr. Smith is featured in a patient story about a cancer survivor who beat non-Hodgkin lymphoma by participating in a clinical trial of an aggressive treatment regimen.
In this Cancer.Net video, Dr. Smith provides an introduction to bone marrow/stem cell transplants as a cancer treatment.
Smith SM, Johnson JL, Niedzwiecki D, Eder JP, Canellos G, Cheson B, Bartlett NL. Sequential topoisomerase I (topo I) and topoisomerase II (topo II) inhibitors in relapsed/refractory aggressive NHL: Results of CALGB 59906, a phase II study of doxorubicin and topotecan. Leukemia & Lymphoma, 2006; 47(8): 1511 – 1517.
Smith SM, Grinblatt D, Cheson B, Bartlett NL. A phase II trial of thalidomide for patients with relapsed or refractory low grade non-Hodgkin’s lymphoma. Br J Haematol. 2008 Feb;140(3):313-9.
Smith SM, van Besien K, Carreras J, Vose JM, Lazarus H, Parameswaren H. Clinical outcome of a second autologous stem cell transplantation for NHL and HL patients relapsing after a first autologous stem cell transplant: An IBMTR analysis. Biology of Blood Marrow Transplantation 2008 Aug: 14/8): 904
Smith SM, van Besien K, Karrison T, Dancey J, McLaughlin P, Younes A, Smith S, Stiff P, Lester E, Modi S, Doyle LA, Vokes EE, Pro B. Temsirolimus (TORISELTM, CCI-779) has activity in non-mantle cell NHL subtypes: The University of Chicago Phase II Consortium. J Clin Oncol. 2010 Nov 1;28(31):4740-6. Epub 2010 Sep 13.
Fowler N, Kahl B, rosen P, Matous J, Cashen A, Jacobs S, Letzer J, Amin B, Williams M, Swan F, Smith S, Saleh A, Shi H, Parasuraman S, Cheson BD. Bortezomib, Bendamustine, and Rituximab in Patients with Relapsed or Refractory Follicular Lymphoma: The Phase 2 VERTICAL Study (in press, JCO)
Piekarz RL, Frye R, Prince HM, Kirschbaum MH, Zain J, Allen SL, Jaffe ES, Ling A, Turner M, Peer CJ, Figg WD, Steinberg SM, Smith S, Joske D, Lewis I, Hutchins L, Craig M, Fojo AT, Wright JJ, Bates SE. Phase II trial of romidepsin in patients with peripheral T-cell lymphoma. Blood. 2011 Feb 25. [Epub ahead of print]
Chiu BCH, Kwon S, Evens AM, Surawicz T, Smith SM, Weisenberger DD. Dietary intake of fruit and vegetables and risk of non-Hodgkin lymphoma (in press, Cancer Causes and Control)